TA-7552

TA-7552 is a potent cholesterol-lowering agent.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

TA-7552 is a potent cholesterol-lowering agent. When TA-7552 is mixed with unsupplemented CLEA CE-2 powder in a concentration of 0.05% and administered to rats for 7 days, TA-7552 does not reduce the normal level of serum cholesterol. The hypocholesterolemic effect of TA-7552 is apparent at the lowest concentration (0.01%) of the drug in the diet, corresponding to a daily dose of ~10 mg/kg body weight, and maximal at the highest concentration of 0.2% TA-7552, lowering serum total cholesterol by 72% while elevating serum HDL cholesterol by 88%. TA-7552 also dose dependently suppresses this rise of hepatic cholesterol, and its lowering rate at the maximal dose is 90%[1].

Male Sprague-Dawley rats (4 weeks of age) are used in this experiment. In the mechanism study, rats are divided into two or three groups of 4 to 6 animals so that the mean body weight, which varies from 210 g to 330 g, is similar between the groups. The experimental groups are treated with TA-7552 (0.1% in CE-2 powder) or cholestyramine (5% in CE-2 powder) by feeding the diet ad libitum for a period of time; The control groups are fed CE-2 powder. When the feces are collected, the animals are individually housed in a metabolic cage, and the collected feces are lyophylized and stored at -20°C[1].

[1]. Takashima K, et al. The hypocholesterolemic action of TA-7552 and its effects on cholesterol metabolism in the rat. Atherosclerosis. 1994 Jun;107(2):247-57.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline